Fact-checked by Grok 2 weeks ago

Stemcell Technologies

STEMCELL Technologies Inc. is a privately owned Canadian biotechnology company headquartered in Vancouver, British Columbia, specializing in the development and manufacture of high-quality cell culture media, cell separation technologies, instruments, accessory reagents, and educational resources for life science research. Founded in 1993 by scientists Dr. Allen C. Eaves and Dr. Connie J. Eaves, the company focuses on advancing research in key areas including stem cell biology, immunology, cancer, regenerative medicine, and cellular therapies, serving scientists worldwide through innovative products that enable reproducible and efficient experimentation. With a commitment to the principle of "Scientists Helping Scientists," STEMCELL reinvests all profits into research and development to support cutting-edge discoveries. The origins of STEMCELL trace back to the early 1980s at the Terry Fox Laboratory of the British Columbia Cancer Agency in Vancouver, where the Eaveses identified a critical need for standardized, cost-effective tissue culture media to study hematopoietic stem cells. In response, they developed MethoCult™, a semi-solid methylcellulose-based medium that became the global gold standard for quantifying hematopoietic stem and progenitor cells, initially produced in their research lab. Launching as an independent company in 1993 with initial funding from a Canadian government loan and personal investment—including Allen Eaves mortgaging his home to build a manufacturing cleanroom—STEMCELL quickly expanded its product portfolio to include cell isolation systems like EasySep™ and instruments such as the RoboSep™-S, addressing broader needs in cell-based assays and therapies. As of 2025, STEMCELL operates as Canada's largest company, employing between 1,000 and 5,000 people across global offices in , , , and , and offering over 2,500 reagents and tools to support diverse applications from to clinical development. The company has achieved significant milestones, including celebrating its 30th anniversary in 2023 with unprecedented annual growth and receiving the Canada's Best Managed Companies award in 2019, as well as the Canada's Most Admired Corporate Cultures award in 2023. In March 2025, the Canadian federal government invested $49.9 million to support the construction of two new facilities, enhancing production of critical inputs for and therapies amid growing global demand. In June 2025, STEMCELL acquired Cellular Highways Ltd. to advance processing technologies and launched the STEMprep™ Dissociator ; in 2025, it partnered with the International Society for Research (ISSCR) to offer a free educational course on stem cell standards. Through ongoing innovations and strategic partnerships, such as with Biosystems for advanced analysis, STEMCELL continues to drive progress in life sciences while prioritizing , , and ethical practices.

Overview

Founding and leadership

STEMCELL Technologies was founded in 1993 by Dr. Allen Eaves and Dr. Connie J. Eaves, a hematologist-oncologist specializing in research, to address the growing demand for standardized and cost-effective media tailored for hematopoietic stem cells. At the time, Eaves was leading research at the Laboratory for Hematology/Oncology Research within the BC Cancer Agency in , , where his work on blood-forming stem cells highlighted the limitations of existing reagents in supporting reproducible experimental outcomes. This initiative stemmed directly from his academic efforts to develop reliable tools for advancing stem cell biology, marking the company's origins as a startup focused on bridging research needs with practical solutions. Dr. Allen Eaves has served as the founder, president, and CEO of STEMCELL Technologies since its inception, guiding its direction with insights from his extensive background in and research. His leadership at the BC Cancer Agency, where he co-founded the Laboratory and directed it for 25 years from 1981 to 2006, profoundly influenced the company's emphasis on high-quality reagents for hematopoietic applications. Under Eaves' stewardship, the company began operations as a privately held entity in , , operating initially from modest facilities to commercialize research-grade products. This private ownership structure allowed for agile decision-making aligned with scientific priorities from the outset. In 2024, Dr. Allen Eaves and the late Dr. Connie J. Eaves were inducted into the BC Innovators Hall of Fame for their contributions.

Mission and focus areas

Stemcell Technologies' mission is to advance the pursuit of scientific by supplying high-quality, innovative , tools, and services that enable faster, more reproducible life science . This purpose stems from the company's founding motivation to address critical needs in , supporting scientists in exploring complex biological processes. The organization envisions its products being utilized in labs worldwide to facilitate groundbreaking discoveries in life sciences. The company's primary focus areas encompass biology, , , , , and cellular therapies. These domains guide product development and resource allocation, emphasizing tools that support reproducible outcomes in areas such as differentiation and immunomodulatory studies. By prioritizing these fields, Stemcell Technologies aims to accelerate progress in understanding disease mechanisms and developing therapeutic interventions. Central to its operations is the "Scientists Helping Scientists" ethos, which fosters a collaborative where scientific expertise drives and support for the community. This principle manifests through educational resources, including online training programs, webinars, protocols, and publications like The Stem Cell Podcast, designed to enhance researcher skills and knowledge sharing. Additionally, the company integrates initiatives, such as its ISO 14001-certified and commitment to by 2050, to minimize environmental impact while advancing science. Diversity and inclusion efforts are prioritized via a dedicated Program that promotes equitable opportunities regardless of , , or background, alongside social responsibility programs that support and ethical governance.

History

Establishment and early years

Stemcell Technologies was established in 1993 in , , , by scientists Dr. Allen C. Eaves and Dr. Connie J. Eaves, hematologists and cancer researchers at the University of British Columbia's Terry Fox Laboratory, to address the growing demand for reliable and standardized tools in research within academic and clinical settings. The company's inception stemmed from frustrations with the inconsistent quality of commercially available media, prompting the Eaveses' team to develop in-house solutions tailored to their studies. This launch marked the beginning of a dedicated venture focused on supporting scientists with high-quality reagents for life sciences research. In its early years, Stemcell Technologies concentrated on creating serum-free media specifically for hematopoietic stem cells, drawing directly from the Eaveses' research requirements at the Terry Fox Laboratory. The flagship product, MethoCult™, a semi-solid methylcellulose-based medium, was introduced in 1993 as the first standardized formulation for culturing and assaying these cells, enabling more reproducible colony-forming unit assays essential for blood stem cell studies. This innovation was followed by StemSpan™, a serum-free expansion medium optimized for the in vitro growth of human hematopoietic progenitors, which addressed key limitations in traditional serum-containing cultures by providing consistent cytokine-supplemented environments. Under Dr. Allen Eaves' ongoing leadership as founder and CEO, these developments laid the groundwork for the company's commitment to scientific rigor in cell culture technologies. Initial operations were modest, beginning with just eight employees in a small facility, where the team handled custom media formulations on a limited scale to meet the needs of local and regional researchers. Distribution was initially confined to North American academic institutions and labs, with products supplied through direct outreach to collaborators in and , fostering early adoption among specialists. These foundational efforts overcame challenges such as sourcing high-purity ingredients and ensuring batch-to-batch consistency, establishing Stemcell as a niche provider of specialized tools for primitive hematopoietic cell research by the late .

Growth and key milestones

In the early 2000s, STEMCELL Technologies marked a pivotal expansion by launching cell separation technologies, including EasySep™ in 2002, transitioning from niche academic support to a broader role in the life sciences market. This move built on the company's foundational work in standardized reagents during the and enabled it to supply reproducible tools for advancing research globally. Remaining under steady private ownership since its , STEMCELL has scaled operations to serve thousands of labs worldwide, achieving an average annual growth rate of 20 percent through reinvestment in and employee . During the , the company adapted swiftly by enhancing its portfolio of tools, including reagents for studying immune responses and developing vaccines, positioning it as an essential partner for efforts. By , this growth had propelled revenue to approximately $150 million and the workforce to over 800 employees, reflecting its maturation into a leading firm. The company's 30th anniversary in 2023 underscored its status as Canada's largest enterprise, with unprecedented annual growth driven by a commitment to accelerating research on cancer and other diseases. A key milestone that year was the opening of a new sales office in Toronto's MaRS Centre, aimed at bolstering its North American footprint and facilitating closer collaboration with scientists in a major innovation hub. In 2024, founders Dr. Allen Eaves and the late Dr. Connie Eaves were inducted into the BC Innovators Hall of Fame for their pioneering contributions to cancer and research over five decades. This expansion aligned with ongoing private strategies that sustained double-digit growth into the mid-2020s, including a $49.9 million from federal in March 2025 to support the construction of two new facilities for cell and gene therapies.

Products and services

Cell culture media and reagents

STEMCELL Technologies provides a range of specialized serum-free and defined formulations optimized for the growth, maintenance, and of stem cells, primary cells, and immune cells. These are designed to minimize variability and enhance in protocols by using pre-screened raw materials and excluding animal-derived components where possible, such as in xeno-free and animal component-free options. For instance, mTeSR™1 is a serum-free medium for feeder-free maintenance of pluripotent stem cells, supporting robust expansion with consistent performance across batches. Similarly, ImmunoCult™-XF T Cell Expansion Medium enables serum-free expansion of T cells with high viability over extended culture periods, without the need for additional supplementation. Key product lines include MethoCult™, a series of methylcellulose-based semi-solid media tailored for hematopoietic progenitor cell assays. MethoCult™ formulations, such as MethoCult™ H4434 for human cells, promote the growth and enumeration of colony-forming units (CFUs) from bone marrow or peripheral blood, facilitating reliable quantification of progenitor activity in colony-forming assays. Another prominent line is NeuroCult™, which consists of media and supplements for culturing primary neurons, neural stem, and progenitor cells derived from human, mouse, or rat tissues. NeuroCult™ supports both proliferation as neurospheres and differentiation into neurons and glia, with options like NeuroCult™-XF for xeno-free conditions to ensure translational relevance. These media often incorporate supplements such as growth factors and cytokines to direct specific cellular functions. For example, STEMdiff™ lineage kits include recombinant cytokines like BMP4 and activin A to induce differentiation of pluripotent stem cells into mesodermal or endodermal s, promoting efficient and standardized outcomes in studies. EpiCult™ Plus Medium, serum- and bovine pituitary extract-free, is supplemented with to enhance proliferation of epithelial stem cells from various tissues. In January 2024, STEMCELL acquired Propagenix Inc., expanding its epithelial capabilities with the EpiX™ technology—previously licensed for research—and Conditional Reprogramming technology for growing tumors and healthy tissues, supporting applications in , , and clinical . In addition to base media, STEMCELL Technologies offers reagents such as buffers, dyes, and detection assays specifically for assessing viability, , and . Trypan Blue serves as a vital dye for manual counting of viable mammalian s by excluding non-viable s with compromised membranes. For tracking, CFDA-SE (carboxyfluorescein succinimidyl ester) labels s for long-term monitoring of division rates in or applications. Resazurin-based assays provide a non-toxic method to measure viability and metabolic activity through fluorescence or absorbance changes. Differentiation studies benefit from tools like the ALDEFLUOR™ Kit, which detects activity—a marker of and s—via a fluorescent substrate for isolation and evaluation. Buffers such as Annexin V Binding Buffer support detection by enabling specific labeling of exposure on surfaces. These reagents ensure precise quantification and in workflows.

Cell separation technologies

Cell separation technologies developed by STEMCELL Technologies enable the isolation of specific cell populations from heterogeneous samples, such as peripheral blood mononuclear cells (PBMCs) or , which is essential for stem cell research and therapeutic applications. These methods primarily rely on immunomagnetic principles, utilizing monoclonal antibodies conjugated to magnetic particles to target cells for selective separation without the need for gradient or column-based systems. The EasySep system represents a of these technologies, offering a manual, column-free immunomagnetic separation approach that achieves high-purity isolation of target cells in as little as 8 minutes. It employs Tetrameric Antibody Complexes (TAC) to magnetic particles to cells via specific surface markers, allowing labeled cells to be retained by a while unbound cells are decanted. This system is optimized for rapid enrichment of diverse cell types, including hematopoietic stem cells (e.g., + cells), immune cells like T cells and B cells, and tumor cells from various sample sources such as or products. Studies have demonstrated its efficacy in obtaining untouched, viable cells with purities exceeding 95% for + hematopoietic progenitors, preserving cell functionality for downstream analyses. In March 2024, the EasySep Human CD138 Positive Selection Kit received FDA Class II classification as an diagnostic device, enabling enrichment of CD138+ plasma cells from to improve diagnostics by enhancing detection of genetic abnormalities. Building on EasySep technology, the RoboSep platform automates the immunomagnetic separation process to support high-throughput workflows in research and clinical settings. Instruments such as the RoboSep-S and RoboSep-16 enable walk-away automation for positive or negative selection from up to 16 samples simultaneously, minimizing hands-on time and reducing variability between runs. The RoboSep-C variant further incorporates a closed-system design to maintain sterility, making it suitable for Good Manufacturing Practice (GMP)-compliant isolations of therapeutic cells like regulatory T cells. Research applications have validated its performance in large-scale isolations, yielding highly pure populations of untouched cells with recovery rates comparable to manual methods but with enhanced reproducibility. Accessory kits complement these systems by providing customizable components for targeted selections, including pre-formulated antibody cocktails and dextran-coated magnetic particles tailored to specific cell markers. For positive selection, kits like the EasySep Human Positive Selection Kit use bispecific to directly isolate + hematopoietic stem , achieving enrichments that support engraftment studies. Negative selection variants deplete unwanted to yield untouched targets, such as naive T , preserving natural phenotypes without . These accessories, including the EasySep for separations and release for particle-free outputs, ensure flexibility across protocols. Isolated from these technologies can be directly integrated with media for expansion in downstream workflows. In June 2025, STEMCELL acquired Cellular Highways Ltd., adding the Highway1 instrument with Vortex-Actuated (VACS™) technology for GMP-ready, sterile of fragile in closed systems, complementing immunomagnetic methods for and applications.

Instruments and accessories

STEMCELL Technologies provides a range of instruments and accessories designed to support the handling, storage, expansion, and analysis of stem cells, emphasizing and in research and therapeutic applications. Central to their cryopreservation offerings is the CryoStor® series of cryoprotectant media, which are serum-free, animal component-free formulations containing DMSO for protecting cells during freezing and storage at ultra-low temperatures, such as -80°C or . These media are optimized for maintaining high post-thaw viability in sensitive cell types, including human pluripotent stem cells and hematopoietic progenitors, when used in conjunction with controlled-rate freezers that gradually reduce temperatures to minimize formation and cellular damage. Complementing these protectants, STEMCELL Technologies offers the ThawSTAR® CFT2 Automated Thawing System, a compact, water-free that ensures consistent and sterile thawing of cryogenic vials directly in cabinets, reducing variability compared to traditional water bath methods and preserving integrity for downstream applications. This instrument supports controlled thawing rates to achieve viabilities exceeding 80% for cryopreserved stem cells, and it includes accessories like confirmation vials for performance validation and audit trails. Additionally, the ThawSTAR® CFT2 Transporter facilitates safe handling and short-distance transport of frozen samples from storage to thawing stations. In July 2024, STEMCELL launched the CellPore™ System, a benchtop mechanoporation using cell squeezing to deliver nucleic acids and proteins into with high efficiency and minimal perturbation, supporting engineering for and therapies; it includes single-use cartridges and complements existing isolation and tools. For scalable , particularly in three-dimensional cultures relevant to , STEMCELL Technologies partners with Biotech to distribute the , a single-use vessel system that enables gentle agitation and oxygenation for growing cultures of pluripotent cells and their derivatives. This supports volumes up to several liters while maintaining cell pluripotency and viability, making it suitable for transitioning from lab-scale to process development for therapies involving neurons, cardiomyocytes, or other lineages. In September 2024, STEMCELL entered a with BioSystems to distribute the Maestro Pro™ and Maestro Edge™ multielectrode array systems in and Europe, integrating them with STEMCELL's (iPSC)-derived neurons, cardiomyocytes, BrainPhys™ Neuronal Medium, and STEMdiff™ differentiation kits to streamline electrophysiological analysis of excitable cells in neural and cardiac research. Among supporting accessories, STEMCELL Technologies provides tools for precise cell quantification and manipulation, such as the STEMvision™ automated imaging system, which uses software-driven analysis to count hematopoietic colony-forming units in assays, offering standardized results with reduced manual error. Manual options include the Bright-Line™ for nucleated cell counting via trypan blue exclusion, compatible with stem cell workflows requiring viability assessments. Serological pipettes and related disposables are recommended in protocols for accurate volume transfer during cell handling, while expansion kits like the STEMdiff™ Cardiomyocyte Expansion Kit include optimized components for differentiating and proliferating induced pluripotent -derived cardiomyocytes in scalable formats. These accessories integrate seamlessly with outputs from cell separation processes, enhancing overall workflow efficiency.

Global presence and operations

Headquarters and facilities

STEMCELL Technologies is headquartered in Vancouver, British Columbia, Canada, at 1618 Station Street, where the company was established in 1993 to support the production and distribution of specialized cell culture media developed from research at the nearby Terry Fox Laboratory. The Vancouver headquarters serves as the central hub for research and development (R&D) laboratories, manufacturing operations, and administrative functions, enabling the company to integrate innovation, production, and management under one primary location. Key facilities at the headquarters include state-of-the-art production sites dedicated to manufacturing cell culture media and reagents, alongside quality control laboratories that operate under a Quality Management System certified to ISO 13485:2016 for medical devices and ISO 9001:2015 for general quality standards. These labs ensure rigorous testing and compliance for products used in life sciences research. Additionally, the facilities house training centers that support the company's "Scientists Helping Scientists" initiative, offering hands-on workshops, customized training programs, and technical education to advance research collaboration and skills development. In recent years, STEMCELL has expanded its Canadian infrastructure with a new facility in , , opened in 2024, which complements the operations by enabling large-scale GMP-compliant production for clinical applications in cell and gene therapies. In March 2025, the Canadian federal government invested $49.9 million to support the construction of two additional facilities in , , to expand production capacity for cell and gene therapies. To enhance , the company has implemented upgrades across its and facilities, including energy-efficient HVAC systems, LED lighting, and equipment designed to reduce and carbon output, aligning with its ISO 14001:2015-certified . These improvements support efficient global supply chains while minimizing environmental impact.

International expansion

STEMCELL Technologies began its international expansion in the early to better serve global researchers in life sciences, establishing offices and distribution centers outside its Canadian headquarters to facilitate faster product delivery and localized support. By 2017, the company opened a major facility in , , consolidating its European operations in an 18,000-square-foot building at Cambridge Research Park to enhance sales, technical assistance, and product processing for the region. In , STEMCELL maintains a key site near in Saint Égrève, which handles inventory, processing, and shipping across Europe, supporting efficient distribution to continental customers. In the United States, STEMCELL has focused on key biotech hubs, with a distribution center in (near ), , enabling overnight delivery to domestic labs and researchers. The company also operates an office at 222 Third Street in , near , to provide direct sales and technical support in the densely populated East Coast research ecosystem. These U.S. expansions underscore STEMCELL's strategy to embed itself in major innovation centers, ensuring proximity to academic and industry users of its cell culture and separation products. Across , STEMCELL has grown its footprint to meet rising demand in emerging biotech markets, with offices in for operations and in , , to support sales and application expertise in the region. Additional locations include three sites in (, , and ) and one in the Republic of Korea, alongside a warehouse in , , to streamline logistics and technical services for customers. This network allows STEMCELL to offer localized training, product demonstrations, and rapid shipping, aiming for comprehensive availability of its and instruments in labs worldwide. To align with diverse regulatory landscapes, STEMCELL adapts its offerings for international compliance, such as manufacturing certain cellular therapy tools under cGMP standards at its European facilities to meet requirements for advanced therapy medicinal products. In 2023, the company further expanded within by opening a sales office in at the MaRS Centre, enhancing its Canadian presence amid growing domestic research activity.

Research and innovation

Key contributions to stem cell research

STEMCELL Technologies has significantly advanced (HSC) research by developing serum-free media formulations, such as StemSpan™, that enable reproducible expansion of human HSCs and cells (HSPCs). These media support the of quiescent HSCs while maintaining their self-renewal and multilineage differentiation potential, addressing key challenges in scaling up cell numbers for therapeutic applications. This has directly contributed to therapies by facilitating the culture of leukemic stem and cells, allowing researchers to study disease mechanisms and test targeted interventions in controlled environments. Furthermore, StemSpan™ has supported transplant research through enhanced expansion of blood-derived HSCs, improving engraftment efficiency in preclinical models and paving the way for reduced reliance on matched donors. In the field of induced pluripotent stem cell (iPSC) research, STEMCELL Technologies' mTeSR™ media have provided a feeder-free platform for maintaining pluripotency and directing into lineage-specific cells, accelerating the creation of patient-derived models. These tools have enabled the generation of iPSC-derived neurons and glial cells for neurological disorders. For , mTeSR™-cultured iPSCs have been used in modeling. The company's innovations in xeno-free media, including TeSR™-XF and PluriPro™, have minimized risks of xenogenic and , essential for advancing regenerative therapies toward clinical use. These defined, animal-component-free formulations maintain viability and functionality without or animal-derived matrices, enabling scalable production of clinical-grade cells for repair. By standardizing conditions, such media have facilitated the translation of iPSC- and MSC-based therapies for applications like and organ regeneration. This reduction in contamination risks has broadened the safety profile of products, supporting faster progression from bench to bedside in .

Collaborations and partnerships

STEMCELL Technologies has established numerous partnerships with research institutions to co-develop protocols for cellular therapies. For instance, in November 2024, the company collaborated with Genome British Columbia and researchers at the University of British Columbia to accelerate stem cell differentiation and development, aiming to enhance applications in disease modeling and regenerative medicine. Historically rooted in British Columbia's research ecosystem, STEMCELL maintains ties with organizations like the BC Cancer Agency through reagent scaling for diagnostic projects and ongoing support via donations to the BC Cancer Foundation, including a $300,000 contribution in 2023 to advance cancer research. Internationally, partnerships with labs such as those in Israel and the United States have focused on protocol optimization; a notable example is the 2022 collaboration with SQZ Biotechnologies to develop a research-use-only microfluidic system for rapid cell therapy production, enabling preclinical studies in under 10 hours. The company also partners with biotechnology firms to integrate its tools into automated workflows, particularly for advanced manufacturing processes like CAR-T cell therapy. In April 2022, STEMCELL entered a supply agreement with Applied Cells to provide high-performance cell separation solutions compatible with automated systems, streamlining T cell isolation for CAR-T production and decentralized manufacturing. Similarly, a 2024 partnership with Axion BioSystems allows STEMCELL to distribute microelectrode array systems, facilitating automated analysis of excitable cells in immunotherapy workflows. For CAR-T-specific advancements, STEMCELL licensed T cell expansion reagents to GE Healthcare in 2023, supporting the generation of chimeric antigen receptor T cells and TCR-engineered T cells for clinical applications. Additionally, the June 2025 expansion of its agreement with CollPlant incorporates recombinant human collagen into clinical-scale manufacturing of cell therapies, enhancing biocompatibility in automated organoid and tissue culture processes. Educational initiatives form a key pillar of STEMCELL's partnerships, with collaborations aimed at scientists in techniques. In August 2025, STEMCELL partnered with the International Society for Stem Cell Research to launch a free on-demand course on ethical standards for human use, providing structured for global researchers. The company offers virtual lab programs and workshops through its own curriculum, covering experimental workflows for and separation. Annually, STEMCELL allocates over $1 million in research grants and in-kind support to universities, including co-op programs that have employed hundreds of students in the past five years, fostering hands-on with company products. These efforts extend to joint events, such as Research Round Tables on quality and biology, co-organized with academic experts to promote best practices.

References

  1. [1]
    About Us - STEMCELL Technologies
    STEMCELL Technologies Inc. is a Canadian biotechnology company that develops specialty cell culture media, cell isolation systems and accessory products for ...
  2. [2]
    A Letter from STEMCELL's Founder & CEO
    ### Founding Story, History, and Key Milestones of STEMCELL Technologies
  3. [3]
    Working at STEMCELL Technologies - Glassdoor
    Rating 2.6 (710) STEMCELL Technologies overview · jobs.stemcell.com · Vancouver, Canada · 1001 to 5000 Employees · 16 Locations · Type: Company - Private · Founded in 1993 · Revenue: ...
  4. [4]
    STEMCELL Technologies | LinkedIn
    Apr 19, 2025 · About us. STEMCELL Technologies is a Canadian biotechnology company that helps power leading-edge life science research around the world.
  5. [5]
    STEMCELL Technologies Celebrates 30 Years with Unprecedented ...
    Jul 12, 2023 · STEMCELL Technologies, Canada's largest biotechnology company, is marking its 30th year of accelerating research into cancer and other diseases.Missing: achievements | Show results with:achievements
  6. [6]
    STEMCELL Technologies Wins Deloitte Best Managed Companies ...
    Mar 7, 2019 · STEMCELL Technologies is proud to announce that the company has been selected as a winner of Canada's Best Managed Companies program for 2019.Missing: achievements | Show results with:achievements
  7. [7]
    STEMCELL Technologies Wins a Canada's Most Admired ...
    Nov 23, 2023 · STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and ...Missing: achievements | Show results with:achievements
  8. [8]
    Federal government invests $49.9 million in STEMCELL ...
    Mar 19, 2025 · STEMCELL Technologies Canada Inc. to build two new cutting-edge biomanufacturing facilities to produce critical inputs used in the ...
  9. [9]
    Harnessing Combined Expertise: STEMCELL Technologies and ...
    STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay ...<|control11|><|separator|>
  10. [10]
    Allen Eaves | Terry Fox Laboratory - BC Cancer Research
    Allen co-founded the Terry Fox Laboratory for Hematology/Oncology Research and served as the lab's Director for 25 years (1981-2006).
  11. [11]
    [PDF] BR27164-Enabling Life Science Research - STEMCELL Technologies
    STEMCELL was founded in 1993 as an independent company by Dr. Allen ... MethoCult™ media for hematopoietic stem cells. 2007. Australia office opened.
  12. [12]
    Neuroscience Research - STEMCELL Technologies
    Explore scientific resources for your neural research, including videos, webinars, wallcharts, protocols, and more.
  13. [13]
    Cell Therapy Research - STEMCELL Technologies
    Cell therapy research investigates using cells to treat diseases by transferring live cells into patients, acting as 'living drugs'.
  14. [14]
    STEMCELL Technologies
    STEMCELL Technologies develops cell culture media, cell separation systems, instruments and other reagents for use in life sciences research.Support · About · Locations · Search our Job Opportunities...
  15. [15]
    Our Responsibility | STEMCELL Technologies
    We adhere to the highest standards of employee well-being; diversity, equity and inclusion; health and safety; good governance; and environmental stewardship.
  16. [16]
    Social Impact - STEMCELL Technologies
    Our Diversity Program aims to ensure STEMCELL is an inclusive workplace for individuals regardless of gender, race, national or ethnic origin, color, religion, ...
  17. [17]
    5 Questions: Stemcell Technologies founder and CEO Allen Eaves ...
    Jul 17, 2023 · Eaves remortgaged his home and took a government loan to start his own business in 1993. 1. You founded Stemcell Technologies back in 1993.
  18. [18]
    Allen C. Eaves - Wikipedia
    Starting with 8 employees in 1993, STEMCELL Technologies Inc has grown at approximately 20% per annum and in by the spring of 2018 had over 1,000 employees ...Education · Career · Select published papers
  19. [19]
    https://www.stemcell.com/our-responsibility
  20. [20]
    STEMCELL Technologies Is an Essential Industry Partner for COVID ...
    Apr 7, 2020 · Vancouver biotechnology company provides critical tools, reagents, and scientific expertise for COVID-19 research globally.Missing: private ownership adaptations
  21. [21]
    STEMCELL Technologies export story spans 20 years
    Sep 1, 2016 · STEMCELL's exporting journey began by selling into the US and through distributors in Asia and Europe. Once it had the resources to build direct-sales channels ...Missing: history formulations
  22. [22]
    STEMCELL Technologies Expands into Toronto's MaRS Centre ...
    Oct 26, 2023 · STEMCELL will take up occupancy at MaRS' West Tower, a LEED Gold building, at 661 University Avenue. “As a company of Scientist Helping ...
  23. [23]
    StemCell Technologies 2025 Company Profile - PitchBook
    StemCell Technologies, founded in 1993, develops life science research products like cell culture media and cells, and is in the biotechnology industry.
  24. [24]
    Cell Culture Media and Supplements - STEMCELL Technologies
    Find cell culture media and supplements optimized for various applications and cell types, including stem cells, immune cells, organoids, and many more.Missing: first commercial 2000
  25. [25]
    mTeSR™1 cGMP Pluripotent Stem Cell (PSC) Maintenance Medium
    Use this specialized, feeder-free culture medium to achieve more consistent human pluripotent stem cell (hPSC) cultures with homogenous, undifferentiated ...Missing: early | Show results with:early
  26. [26]
    ImmunoCult™-XF T Cell Expansion Medium, Serum-Free, Xeno-Free
    No need to supplement the medium with serum · Supports robust T cell expansion with high viability after 10 - 12 days of culture · Expanded T cells are able to ...
  27. [27]
    MethoCult™ Methylcellulose-Based Media - STEMCELL Technologies
    MethoCult™ is a line of semi-solid methylcellulose-based media formulated to promote optimal growth and differentiation of hematopoietic progenitor cells in ...
  28. [28]
    MethoCult™ H4434 Classic Methylcellulose Medium (Human)
    A complete methylcellulose-based medium for the growth and enumeration of hematopoietic progenitor cells in colony-forming unit (CFU) assays.
  29. [29]
    NeuroCult™ Neural Stem Cell Culture Media
    NeuroCult™ is a line of culture media and reagents for primary neurons, CNS-derived neural stem and progenitor cells, and brain tumor stem cells.
  30. [30]
    EpiCult™ Plus Epithelial Stem Cell Culture Medium
    A serum- and BPE-free cell culture medium that supports increased proliferation of epithelial stem cells compared to conventional media
  31. [31]
    Cell Dyes and Detection Assay Kits - Product Types - Products
    ### Summary of Reagents Offered by STEMCELL Technologies
  32. [32]
    CFDA-SE | Cell Proliferation and Tracking Dye
    $$155.00CFSE (carboxyfluorescein succinimidyl ester) is a dye often used to assay cell proliferation and motility, and for in vivo cell tracking experiments.
  33. [33]
    EasySep™ Magnetic Cell Separation—The Easy Choice
    Discover EasySep™ immunomagnetic cell isolation—a simpler, easier way to isolate the cells you need. This versatile platform combines the specificity of ...
  34. [34]
    How EasySep™ Magnetic Cell Separation Technology Works
    EasySep™ is a fast and easy immunomagnetic cell separation technology that allows you to isolate virtually any cell types from a variety of sample sources ...
  35. [35]
    EasySep™ 8-Minute Human Cell Isolation Kits
    Isolate human immune cells in as little as 8 minutes with our EasySep™ human cell isolation kits. Isolated cells are highly purified, functional and ready ...
  36. [36]
    EasySep™ Human T Cell Enrichment Kit - STEMCELL Technologies
    Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of ...
  37. [37]
    Isolation of subsets of immune cells - PubMed
    StemCell Technologies Inc., Vancouver, British Columbia, Canada. PMID ... The EasySep immunomagnetic system can be used with cell suspensions from a variety of ...<|control11|><|separator|>
  38. [38]
    RoboSep™ - Automated Cell Separation Instruments
    RoboSep™ is a fully automated cell isolation system that automates cell processing and isolations, minimizing sample handling and cross-contamination.
  39. [39]
    RoboSep™-16 Automated Cell Separation Instrument
    The RoboSep™-16 is a fully automated cell separator for up to 16 samples, using immunomagnetic technology for positive or negative selection. It isolates cells ...
  40. [40]
    RoboSep™-C Automated Closed Cell Separation System
    RoboSep™-C is an automated, closed-system immunomagnetic instrument for high-throughput cell isolation, automating cell processing in a sterile environment.
  41. [41]
    Large-scale Isolation of Highly Pure "Untouched" Regulatory T Cells ...
    This procedure, which uses an antibody cocktail and magnetic beads for separation in an automated system (RoboSep), was scaled up and adapted to be ...<|control11|><|separator|>
  42. [42]
    EasySep™ PE Positive Selection Kit II - STEMCELL Technologies
    The EasySep™ PE kit uses immunomagnetic positive selection to isolate PE-labeled cells. It labels cells with antibodies and magnetic particles, then uses a  ...
  43. [43]
    EasySep™ Human "Do-It-Yourself" Positive Selection Kit II
    The EasySep kit uses immunomagnetic positive selection to isolate human cells of interest from single-cell suspensions, using a magnetic system and no columns.
  44. [44]
    EasySep™ Human T Cell Isolation Kit - STEMCELL Technologies
    Easily and efficiently isolate human T cells in as little as 8 minutes with EasySep™. Use simple, optimized protocols trusted by scientists for over 20 ...
  45. [45]
    EasySep™ Magnet for Cell Separation - STEMCELL Technologies
    Easily and efficiently perform magnetic cell separation procedures by using the EasySep™ Magnet with EasySep™ cell isolation reagents. The EasySep™ Magnet ...
  46. [46]
    CryoStor® CS10 Cell Freezing Medium | STEMCELL Technologies
    CryoStor® CS10 is an animal protein-free, serum-free cryopreservation medium containing 10% DMSO to prepare & preserve cells in ultra low temperatures.Missing: freezers | Show results with:freezers
  47. [47]
    Cryopreservation Basics: Protocols and Best Practices for Freezing ...
    Resuspend the cells in a freezing media suitable for your cell type. A freezing media such as CryoStor® CS10 can be used for most cell types. You can also ...
  48. [48]
    ThawSTAR® CFT2 Automated Thawing System
    Using this convenient and compact system, you can thaw your cells directly in the biosafety cabinet. Simply insert a frozen cryogenic vial and retrieve it.
  49. [49]
    ThawSTAR® CFT2 IOPQ Kit - STEMCELL Technologies
    The ThawSTAR® CFT2 IOPQ Kit includes installation, operational, and performance qualification documentation and testing tool accessories to facilitate ...
  50. [50]
    PBS-MINI MagDrive Bioreactor | STEMCELL Technologies
    Reliably and rapidly scale up your 3D cell cultures and suspensions with the PBS-MINI MagDrive Bioreactor Base Unit and MAG Single-Use Vessels. The gentle yet ...
  51. [51]
    STEMCELL Technologies and PBS Biotech Partner to Enable ...
    Jun 3, 2022 · STEMCELL Technologies Inc. and PBS Biotech Inc. have announced their supply partnership to make the PBS-MINI Bioreactor available through STEMCELL Technologies.Missing: Excellerate | Show results with:Excellerate
  52. [52]
    STEMvision™ | STEMCELL Technologies
    STEMvision consists of an instrument and software designed specifically for imaging and counting colonies in hematopoietic colony-forming unit (CFU) assays.
  53. [53]
    Hausser Scientific™ Bright-Line Hemocytometer
    Count cells manually at a fraction of the cost and footprint of automated cell counters by using the Hausser Scientific™ Bright-Line Hemocytometer.
  54. [54]
    Locations - STEMCELL Technologies
    Explore below to learn about our global offices and the services and support available in your region.
  55. [55]
    Quality at STEMCELL
    At STEMCELL Technologies, we invest in quality to achieve our goal of advancing scientific knowledge by enabling research.
  56. [56]
    Lab Training Courses and Programs - STEMCELL Technologies
    Learning Centers · Cancer Research · Cardiac and Skeletal Muscle Research · Cell ... Scientists Helping Scientists™; ISO 13485 and ISO 9001 Certified Quality ...
  57. [57]
    Scientists Helping Scientists - STEMCELL Technologies
    As Scientists Helping Scientists, we know that effective training, communication, and collaboration is essential for research to progress. STEMCELL is ...
  58. [58]
    Government of Canada Announces First-of-Its-Kind ...
    Jul 9, 2024 · The expansion of STEMCELL Technologies' presence in British Columbia strengthens the province's status as a biomanufacturing and life sciences ...
  59. [59]
    Environmental Sustainability | STEMCELL Technologies
    STEMCELL has implemented an ISO 14001:2015-certified Environmental Management System at our Canadian-based operations to monitor, measure, analyze, and evaluate ...
  60. [60]
    STEMCELL Technologies Opens New Office and Laboratories in ...
    Jan 31, 2017 · STEMCELL recently took possession of an 18,000 square foot building located in the Cambridge Research Park. STEMCELL has now consolidated ...Missing: international expansion
  61. [61]
    Saint Égrève, France - STEMCELL Technologies
    STEMCELL's facility, located just outside of Grenoble in Saint Égrève, France, is where we inventory, process and ship orders throughout Europe.Missing: Cambridge | Show results with:Cambridge
  62. [62]
    Seattle, WA - STEMCELL Technologies
    Europe · Asia · Oceania ... To serve our US customers, STEMCELL has a distribution center near the Seattle airport to allow overnight delivery to US locations.Missing: office | Show results with:office<|control11|><|separator|>
  63. [63]
    Asia - STEMCELL Technologies
    STEMCELL Technologies has four locations in Asia: two in China, and one each in Singapore and the Republic of Korea.Missing: international expansion offices
  64. [64]
    Oceania - STEMCELL Technologies
    Our sales team is based across Australia and provides customers with sales and customer support, product demos and scientific workshops.Missing: Pacific Singapore Tokyo
  65. [65]
    Regulated Products and Instruments - STEMCELL Technologies
    Products Manufactured Under Relevant cGMPs. The safety and traceability of ancillary materials are key factors when developing any cell therapy product.
  66. [66]
    Tailored Cytokine Optimization for ex vivo Culture Platforms ...
    Sep 24, 2020 · With StemSpanTM (STEMCELL Technologies) medium being more prevalent in latest studies on HSPC ex vivo expansion and in most advanced clinical ...
  67. [67]
    Culturing Leukemic Stem & Progenitor Cells with StemSpan™ Medium
    This Technical Bulletin describes the use of serum-free StemSpan™ medium and supplements for the culture of hematopoietic stem and progenitor cells (HSPCs) ...
  68. [68]
    Distinct signaling programs control human hematopoietic stem cell ...
    Several growth factors (GFs) that together promote quiescent human hematopoietic stem cell (HSC) expansion ex vivo have been identified; however, ...
  69. [69]
    Generation of a human iPSC line CIBi007-A from a patient with ...
    Patient-specific iPSCs have been proven to be a valuable source for disease modeling ... Human iPSCs were maintained in mTeSRTM 1 (STEMCELL Technologies) ...
  70. [70]
    Human iPSC co-culture model to investigate the interaction between ...
    Jul 23, 2022 · iPSCs were cultured in mTeSR™1 (StemCell Technologies) or OXE8 medium on Geltrex™ (Thermo Fisher)-coated tissue culture plates with daily medium ...<|separator|>
  71. [71]
    Human mesenchymal stem cell sheets in xeno-free media ... - Nature
    Oct 8, 2019 · Integrating healing physiology and regenerative potential is reduced by low cell retention and engraftment into target tissues and organs, a key ...
  72. [72]
    Developing standards to support the clinical translation of stem cells
    Nov 1, 2021 · Most countries advocate use of Xeno‐free culture media, feeder cells or a feeder‐free matrix in all cell operating processes to decrease the ...
  73. [73]
    Culture Media Defined: Xeno-Free, Animal Origin-Free, and More
    ... STEMCELL Technologies verifies that raw materials meet our internal animal origin requirements. ... Qualification of Ancillary/Raw Materials for Clinical Use.Missing: translation regenerative
  74. [74]
    Speeding up Stem Cell Research: Genome BC, STEMCELL ...
    Nov 13, 2024 · A new collaboration between Genome BC, STEMCELL Technologies and researchers at the University of British Columbia (UBC) aims to accelerate stem cell research.
  75. [75]
    STEMCELL Scaling Reagents for BC Cancer, UBC, and BCCDC ...
    Dr. Hirst highlights how STEMCELL Technologies is helping to formulate and scale reagents to support the project goals for rapid diagnostic testing.Missing: Agency | Show results with:Agency
  76. [76]
    BC Cancer Foundation's Post - LinkedIn
    Jul 12, 2023 · STEMCELL Technologies is celebrating 30 years of accelerating cancer research with a generous donation of $300,000 to the Foundation.Missing: partnership | Show results with:partnership
  77. [77]
    Collaboration with STEMCELL Technologies on Research-Use-Only ...
    May 5, 2022 · Through our collaboration with STEMCELL, we intend to broaden technology access for research use and hope to facilitate advancement of the cell ...Missing: expansion | Show results with:expansion
  78. [78]
    Applied Cells and STEMCELL Technologies enter Supply Agreement
    Apr 19, 2022 · Applied Cells Inc. and STEMCELL Technologies Canada Inc. have announced their collaboration to deliver a new high-performance cell separation solution.
  79. [79]
    STEMCELL Technologies and Axion BioSystems Partner to ...
    Sep 17, 2024 · The partnership allows STEMCELL to sell Axion's MEA systems, enabling scientists to examine cell interactions and provide comprehensive cell ...
  80. [80]
    https://www.linkedin.com/posts/bccancer-foundation_stemcell-technologies-is-celebrating-30-years-activity-7085015018601078784-1hL
  81. [81]
    COLLPLANT BROADENS ITS COLLABORATION WITH STEMCELL ...
    Jun 9, 2025 · STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and ...
  82. [82]
    The ISSCR and STEMCELL Technologies Partner to Launch Free ...
    Aug 12, 2025 · A company of Scientists Helping Scientists, STEMCELL Technologies is known for providing innovative, high-quality tools and educational ...
  83. [83]
    Working Together to Advance Science - STEMCELL Technologies
    STEMCELL actively contributes to scientific progress by engaging in research collaborations with academic, industry, and government partners around the world.